Alchemia Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
1,475.00
787.00
162.30
-
-
Gross Income
1,475.00
787.00
162.30
-
-
SG&A Expense
19,838.00
15,652.00
2,777.20
557.80
380.90
EBIT
-
16,989.00
2,939.40
557.80
380.90
Unusual Expense
-
12,764.00
-
-
-
Non Operating Income/Expense
14,303.00
11,761.00
24,515.20
7.20
-
Pretax Income
6,614.00
17,828.00
21,716.20
540.30
372.60
Income Tax
262.00
2,937.00
290.20
-
-
Consolidated Net Income
6,352.00
14,891.00
21,426.00
540.30
372.60
Net Income
6,352.00
14,891.00
21,426.00
540.30
372.60
Net Income After Extraordinaries
5,780.00
13,966.00
21,426.00
540.30
372.60
Net Income Available to Common
6,924.00
15,816.00
21,426.00
540.30
372.60
EPS (Basic)
0.02
0.05
0.07
0.00
0.00
Basic Shares Outstanding
324,306.60
324,629.30
324,723.60
324,723.60
324,723.60
EPS (Diluted)
0.02
0.05
0.07
0.00
0.00
Diluted Shares Outstanding
324,306.60
324,629.30
324,723.60
324,723.60
324,723.60
EBITDA
19,838.00
16,202.00
2,777.20
557.80
380.90
Other Operating Expense
-
550.00
-
-
-
Non-Operating Interest Income
396.00
164.00
140.50
10.20
8.20

About Alchemia

View Profile
Address
100 Albert Road
Melbourne Victoria (VIC) 3205
Australia
Employees -
Website http://www.alchemia.net.au
Updated 07/08/2019
Alchemia Ltd. is a biotechnology company, which engages in developing new human therapeutics based on its proprietary drug discovery, drug targeting and synthesis technologies. It involves in the research and development of new human pharmaceuticals. The company also engages in the commercialization and improvements of its generic fondaparinux product.